Alligator Bioscience AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	42.25	57.77	58.11	35.7	12.94	4.35
Other Revenue	3.97	-0.04	1.14	0.31	0.38	1.16
Revenue	46.22	57.72	59.25	36	13.33	5.52
Revenue Growth (YoY)	66.41%	-2.58%	64.58%	170.14%	141.65%	26.55%
Cost of Revenue	106.63	167.21	218.79	147.73	86.98	82.32
Gross Profit	-60.41	-109.48	-159.54	-111.72	-73.66	-76.81
Selling, General & Admin	50.32	70.43	79.38	68.84	56.85	55.71
Other Operating Expenses	0.47	-0.12	-0.02	-0.03	-0	-0
Operating Expenses	94.28	119.04	89.85	80.58	68	67.23
Operating Income	-154.68	-228.52	-249.39	-192.3	-141.65	-144.04
Interest Expense	-47.27	-19.69	-0.48	-0.65	-0.23	-0.31
Interest & Investment Income	0.4	1.31	1.88	-	-	0.19
Currency Exchange Gain (Loss)	-2.34	-1.27	-0.6	-0.46	-0.14	-0.6
Other Non Operating Income (Expenses)	113.97	14.28	0	0	-	-0
EBT Excluding Unusual Items	-89.92	-233.89	-248.59	-193.41	-142.03	-144.75
Gain (Loss) on Sale of Investments	-	-	-	-	-	1.46
Asset Writedown	12.2	-	-	-	-	-
Other Unusual Items	-	-	-	-	-0.96	-
Pretax Income	-77.72	-233.89	-248.59	-193.4	-141.74	-143.3
Net Income	-77.72	-233.89	-248.59	-193.4	-141.74	-143.3
Net Income to Common	-77.72	-233.89	-248.59	-193.4	-141.74	-143.3
Shares Outstanding (Basic)	17	1	0	0	0	0
Shares Outstanding (Diluted)	17	1	0	0	0	0
Shares Change (YoY)	2322.13%	63.72%	103.32%	146.00%	25.61%	-
EPS (Basic)	-4.63	-318.53	-554.27	-876.77	-1580.64	-2007.26
EPS (Diluted)	-4.70	-320.00	-554.27	-880.00	-1580.64	-2010.00
Free Cash Flow	-165.18	-212.43	-191.74	-173.05	-127.08	-141.45
Free Cash Flow Per Share	-9.84	-289.30	-427.53	-784.49	-1417.17	-1981.45
Gross Margin	-130.70%	-189.67%	-269.26%	-	-	-
Operating Margin	-334.68%	-395.90%	-420.90%	-534.16%	-1062.89%	-2611.71%
Profit Margin	-168.15%	-405.19%	-419.55%	-537.22%	-1063.52%	-2598.30%
Free Cash Flow Margin	-357.39%	-368.01%	-323.61%	-480.67%	-953.54%	-2564.90%
EBITDA	-158.97	-227.58	-248.24	-188.89	-136.7	-138.51
D&A For EBITDA	-4.29	0.95	1.15	3.41	4.95	5.53
EBIT	-154.68	-228.52	-249.39	-192.3	-141.65	-144.04
Revenue as Reported	48.07	59.71	61.9	37.14	15.13	6.67

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.